Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Letters
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-1074 Online ISSN: 1792-1082
Journal Cover
September-2015 Volume 10 Issue 3

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
September-2015 Volume 10 Issue 3

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Piwil2 modulates the invasion and metastasis of prostate cancer by regulating the expression of matrix metalloproteinase-9 and epithelial-mesenchymal transitions

  • Authors:
    • Yanfeng Yang
    • Xuepei Zhang
    • Dongkui Song
    • Jinxing Wei
  • View Affiliations / Copyright

    Affiliations: Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China
  • Pages: 1735-1740
    |
    Published online on: June 19, 2015
       https://doi.org/10.3892/ol.2015.3392
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Piwi-like RNA-mediated gene silencing 2 (Piwil2) is an oncogene that is highly expressed in breast, gastric, colorectal and papillary thyroid cancer. As a candidate oncogene, its role in prostrate cancer has yet to be elucidated. In the present study, 30 tumor specimens and four prostate cancer cell lines were analyzed. The total RNA and protein from the specimens and the cells were analyzed using quantitative polymerase chain reaction and western blotting, respectively. The expression of Piwil2 in PC‑3 cells was knocked down using specific small hairpin RNA. Transwell assays and wound‑healing models were used to assess cell invasion and migration. In addition, the expression of several factors associated with epithelial‑mesenchymal transitions (EMT) were evaluated by western blotting. The results revealed that the Piwil2 gene was associated with the Gleason score and the tumor‑node‑metastasis stage of the tumor tissues. Cell invasion and migration decreased significantly in PC‑3 cells with knocked-down Piwil2. In addition, silencing Piwil2 downregulated the expression of N‑cadherin, Twist and vimentin and upregulated the expression of E‑cadherin, factors associated with EMT, and also reduced the expression of matrix metalloproteinase‑9. Piwil2 was demonstrated to possess an important role in the invasive ability of prostate cancer, and therefore, may be a potential therapeutic target for the treatment of this cancer.

Introduction

Prostate cancer has become one of the most common types of cancer, and is currently the second most lethal disease affecting the elderly male population in developed countries. In 2010 and 2013, prostrate cancer led to 80,900 and 33,720 mortalities, respectively (1–3). Although progress has been made in the treatment of prostate cancer, the majority of patients succumb to tumor metastasis. Furthermore, tumors recur in ~30% of patients within 12–18 months of undergoing a prostatectomy (4,5). Therefore, an improved understanding of the molecular mechanisms involved in the pathogenesis of prostate cancer, including those underlying metastasis and invasion, is urgently required.

The Piwi genes, which were identified a number of decades ago, were the first class of genes known to be required for stem cell self-renewal in a diverse range of organisms (6,7). Piwi-like RNA-mediated gene silencing 2 (Piwil2) belongs to the Ago/Piwi family, which is comprised of Piwil1/Hiwi, Piwil2/Hili, Piwil3 and Piwil4/Hiwi2. The human-derived Piwil2 gene regulates RNA silencing and transcription, functions in spermatogenesis, and is involved in the self-renewal and differentiation of normal testis and fetal tissues (8,9). Piwil2, as a candidate oncogene in previous studies, is highly expressed in breast, gastric, colorectal and papillary thyroid cancer, and is closely associated with the occurrence and progression of tumors (10–14).

The association between Piwil2 and prostate cancer is rarely reported. The present study therefore aimed to investigate this association and discern the potential underlying molecular mechanisms.

Methods

Cell lines and primary tumor specimens

The PC-3, 22RV1, DU-145 and LNCaP cell lines (American Type Culture Collection, Manassas, VA, USA) were cultured in RPMI-1640 complete medium (GE Healthcare Life Sciences, Logan, UT, USA) containing 10% fetal calf serum, 100 units/ml penicillin and 100 µg/ml streptomycin. The immortalized normal prostate epithelial cell line RWPE-1 was cultured in keratinocyte serum-free medium containing 0.05 mg/ml bovine pituitary extract and 5 ng/ml recombinant epidermal growth factor (Gibco Life Technologies, Carlsbad, CA, USA). The cell lines were cultivated in a 37°C incubator with 5% CO2. Next, the cells were digested with 0.25% trypsin every three to four days for passage. All cells used in the experiments were in the logarithmic growth phase.

In total, 30 tumor specimens were obtained from patients with prostate cancer at The First Affiliated Hospital of Zhengzhou University (Zhengzhou, China). The patients, who were aged between 45 and 89 years old, underwent a radical prostatectomy, without receiving any other treatments, between July and November 2012. The present study was approved by the Ethics Committee of The First Affiliated Hospital of Zhengzhou University. Informed consent was obtained from each patient, conforming to the tenets of the Declaration of Helsinki (15).

Total RNA extract and reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Human tumor tissues and pericarcinomatous tissues obtained from patients with prostate cancer were immediately frozen in liquid nitrogen and stored at −80°C. The total RNA from the tumor tissues, pericarcinomatous tissues and all aforementioned cell lines were extracted using a total RNA extraction kit, according to the manufacturer's instructions (Invitrogen Life Technologies, Carlsbad, CA, USA). Next, 100 ng total RNA was used for qPCR, according to the instructions of the SYBR Green PCR master mix kit (Invitrogen Life Technologies). Each amplification was performed using one of the following primers: β-actin forward, 5′-CACCCAGCACAATGAAGAT-3′ and reverse, 5′-CAAATAAAGCCTGCCAAT-3′; Piwil2 forward, 5′-TCATGGGGCCATCAGAAG-3′ and reverse, 5′-CCATCCCGATCACCATTAAC-3′; matrix metalloproteinase (MMP)-2 forward, 5′-GATACCCCTTGACGGTAAGG-3′ and reverse, 5′-CCTTCTCCCAAGGTCCATAGC-3′; MMP-9 forward, 5′-GGGACGCAGACATCGTCATC-3′ and reverse, 5′-TCGTCATCGTCGAAATGGGC-3′; E-cadherin forward, 5′-TGCTCTTCCAGGAACCTCTGTG-3′ and reverse, 5′-GGTGACCACACTGATGACTCCTG-3′; N-cadherin forward, 5′-GGTGGAGGAGAAGAAGACCAG-3′ and reverse, 5′-GGCATCAGGCTCCACAGT-3′; vimentin forward, 5′-GGGACCTCTACGAGGAGGAG-3′ and reverse, 5′-CGCATTGTCAACATCCTGTC-3′; and Twist forward, 5′-GCTGTGCTTACTCTAGCCATC-3′ and reverse, 5′-TGAGGCATTTGCTCACATCAC-3′. All PCR experiments were performed in triplicate using the Bio-Rad C1000 Touch™ Thermal Cycler (Bio-Rad Laboratories, Inc., Hercules, CA, USA). PCR was performed under the following conditions: Denaturation at 93°C for 2 min, followed by 40 cycles of 93°C for 1 min, 55°C for 1 min and 72°C for 1 min, and extension at 72°C for 7 min.

Western blot analysis

The cells were lysed at 2–8°C in RIPA solution containing 1% proteasome inhibitor (Beyotime Institute of Biotechnology, Jiangsu, China), for 30 min. The total protein concentration was then determined using the Bradford method. In total, 30 µg of denaturized total protein was loaded into each lane for SDS-PAGE. The bands were then transferred to polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA, USA). The membranes were incubated with blocking buffer (Sigma-Aldrich, St. Louis, MO, USA) containing 5% bovine serum albumin in phosphate-buffered saline for 2 h at room temperature. Incubation was then performed using the primary monoclonal mouse anti-human Piwil2 (dilution, 1:800; cat. no. LS-C62097-100; LifeSpan BioSciences, Inc., Seattle, WA, USA), monoclonal mouse anti-human E-cadherin (dilution, 1:800; cat. no. 5296S; Cell Signaling Technology, Inc., Danvers, MA, USA), monoclonal mouse anti-human N-cadherin (dilution, 1:500; cat. no. 14215S; Cell Signaling Technology, Inc.), polyclonal rabbit anti-human Twist (dilution, 1:800; cat. no. ab50581; Abcam, Cambridge, UK), monoclonal mouse anti-rabbit vimentin (dilution, 1:800; cat. no. 9775S; Cell Signaling Technology, Inc.) and polyclonal mouse anti-human β-actin (dilution, 1:1,500; cat. no. sc-7210; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) antibodies overnight at 4°C. The membranes were subsequently incubated with horseradish peroxidase-conjugated polyclonal rabbit anti-mouse (dilution, 1:4,000; cat. no. A0216; Beyotime Institute of Biotechnology) or polyclonal goat anti-rabbit (dilution, 1:4,000; cat. no. A0239; Beyotime Institute of Biotechnology) secondary antibodies for 2 h at room temperature. Detection was performed using the enhanced chemiluminescent substrate (Bio-Rad Laboratories, Inc.).

Knockdown of the Piwil2 gene using short hairpin RNA (shRNA)

A recombinant lentivirus containing a green fluorescent protein (GFP) reporter and a sequence encoding a Piwil2-specific shRNA (shRNA group) or a scramble shRNA (mock group) was synthesized by Shanghai Rainbow Chemistry Co., Ltd. (Shanghai, China). The sequences of the Piwil2 and scrambled shRNA were 5′-AAACCTTTGGACCCAGCTCTG-3′ and 5′-GTACCGCACGTCATTCGTATC-3′, respectively (14). The PC-3 cells were transfected with viral supernatants according to the manufacturer's instructions. In total, 5×105 cells were washed three times prior to the cell transfection, and 20 pmol shRNA, with 3 µg/ml polybrene in serum-free medium, was added to the cells and incubated at 37°C. Fresh culture medium was added after 6 h. The cells expressing GFP were sorted using a flow cytometer (FACS AriaTM II; BD Biosciences, Franklin Lakes, NJ, USA) when the cells had reached 70–80% confluence. The silencing effect on the Piwil2 gene was assessed by qPCR and western blot analysis, according to the aforementioned protocols.

Tumor invasion and migration

A Transwell unit was used to investigate cellular invasion. The units were placed in 24-well plates and the upper chamber was coated with Matrigel (BD Biosciences). In total, 200 ml of cell solution, at a density of 5×104 cells/ml, resuspended in serum-free medium, was added to the upper chamber, and medium containing 10% fetal bovine serum was added to the lower chamber. Subsequent to a 24-h incubation, the cells that had passed through the membrane were fixed with 4% paraformaldehyde for 15 min, and then stained with crystal violet. The cells in five random fields were counted under an Olympus CX41 light microscope (magnification, x200; Olympus Corporation, Shanghai, China). In addition, a wound-healing assay was performed in order to measure the extent of cell migration. In total, 1×104 PC-3 cells were transplanted into a 24-well plate. When the cells had grown to cover the entire bottom of the plate well, a straight-line scratch was made using a 20-µl pipette tip. Subsequent to a 48-h incubation period in the serum-free medium, images of the cells were captured using an Olympus CKX31 reverse-phase microscope (Olympus Corporation).

Statistical analysis

The data were analyzed using SPSS software version 15.0 (SPSS, Inc., Chicago, IL, USA). The data derived from the tumor invasion assay of the shRNA and mock groups were assessed using a t-test for two independent samples or the rank-sum test for non-normal distribution, and the data are presented as the mean ± standard deviation. A value of P<0.05 was considered to indicate a statistically significant difference.

Results

Expression of Piwil2 in clinically obtained specimens of prostate cancer

In order to investigate the expression of the Piwil2 gene and protein in patients with different histological grades of prostate cancer, RT-qPCR and western blot analysis was performed. Immunohistochemical staining revealed a high expression of Piwi-like protein 2 in prostate cancer cells (Fig. 1A) when compared with adjacent normal tissue (Fig. 1B). The results of RT-qPCR revealed that 83.33% of tumor tissues (25/30) possessed a higher level of Piwil2 than the associated adjacent tissues (Fig. 2A). In addition, Piwil2 expression was positively associated with the Gleason score (P=0.002) and the tumor-node-metastasis (TNM) stage (P=0.003) of the tumor tissue. As shown in Fig. 2B and C, Piwil2 was overexpressed in patients with a high Gleason score (≥8) and an advanced TNM stage (T3-T4).

Figure 1.

Immunohistochemical analysis revealing the expression of the Piwi-like protein 2 (Piwil2). Piwil2 is highly expressed in (A) prostate cancer cells compared with (B) adjacent normal tissue. Scale bar, 200 µm.

Figure 2.

Results of quantitative polymerase chain reaction revealing the expression of the Piwil2 gene in 30 patients. (A) Compared with adjacent normal tissues, the expression of the Piwil2 gene in prostate cancer tissues was significantly higher. The expression of the Piwil2 gene was also significantly higher in patients with (B) a high Gleason score (≥8) and (C) an advanced tumor-node-metastasis stage (T3-T4). *P<0.05.

Expression of Piwil2 in prostate cancer cell lines

RT-qPCR was performed in order to detect the level of Piwil2 in the normal prostate RWPE-1 cell line and in the PC-3, 22RV1, DU-145 and LNCaP prostate cancer cell lines. The level of Piwil2 in the tumor cell lines was higher compared with the normal prostate cell line (Fig. 3A). Of the four prostate cancer cell lines analyzed, Piwil2 expression was highest in the PC-3 cells.

Figure 3.

Knock-down of the Piwil2 gene in the prostate cancer cell lines using specific small hairpin RNA. (A) Compared with the normal RWPE-1 prostate epithelial cell line, an overexpression of Piwil2 mRNA was evident in the PC-3, 22RV1, DU-145 and LNCaP prostate cancer cell lines. (B) Piwil2-targeted shRNA (shRNA group) and scrambled shRNA (mock group) were successfully transfected into PC-3 cells. (C) Western blot analysis revealing that the expression of the Piwil2 gene decreased in the shRNA group. *P<0.05.

Subsequent to transfection with shRNA or mock recombinant lentiviruses, GFP-positive PC-3 cells were collected by flow cytometry, sorted and then cultured (Fig. 3B). The silencing effect on the Piwil2 gene was confirmed by western blot analysis. Compared with the mock group, the Piwil2 gene was significantly downregulated in cells of the shRNA group (Fig. 3C). This demonstrated that the lentivirus-encoding Piwil2-targeted shRNA effectively decreased Piwil2 expression in the PC-3 cells.

Function of Piwil2 in invasion and migration in vitro

For the tumor invasion assay, the number of cells on the lower chamber of the Transwell unit was counted. The number of cells in the shRNA group (49.19±9.09) was significantly lower compared with the mock group (90.43±14.54) (P=0.000; Fig. 4A and B). A wound-healing assay was also performed in order to measure the distance of cell migration in serum-free medium. The difference in the width of the scratch between 0 and 48 h was processed using ImageJ 1.37 software (National Institutes of Health, Bethesda, MA, USA). Knockdown of the Piwil2 gene significantly decreased cell migration in the shRNA group (Fig. 4C and D). The extent of wound closure in the mock group (49.64±5.63) was significantly higher compared with the shRNA group (23.53±2.66) (P=0.000). These results indicate that knock-down of the Piwil2 gene in the PC-3 cells decreased invasion and migration in vitro.

Figure 4.

Effect of Piwil2 knock-down on tumor invasion and migration in vitro. (A) A Transwell assay was used to evalute cellular invasion in the Piwil2-targeted small hairpin (sh)RNA group and the mock group. (B) The number of cells in the shRNA group was significantly lower than in the mock group. Knock-down of the Piwil2 gene decreased (C) cell migration and (D) wound closure in the Piwil2-targeted shRNA group. *P<0.05.

Knockdown of Piwil2 decreases the expression of MMP-2/9 and inhibits epithelial-mesenchymal transitions (EMT)

As MMPs and EMT have important roles in tumor invasion and metastasis, the levels of MMP-2 and -9, together with the expression of the primary biomarkers of EMT, E-cadherin, N-cadherin, vimentin and Twist, were evaluated by RT-qPCR and western blotting. The results revealed that the expression of vimentin, Twist and MMP-9 in the PC-3 cells of the shRNA group was downregulated, but that E-cadherin was upregulated and MMP-2 exhibited no change in expression (Fig. 5A and B).

Figure 5.

Knock-down of Piwil2 in PC-3 cells reduced matrix metalloproteinase (MMP)-9 expression and inhibited epithelial-mesenchymal transitions. The mRNA and protein expression of E-cadherin, N-caderin, vimentin, twist, MMP-2 and -9 were detected by (A) reverse transcription-quantitative polymerase chain reaction and (B) western blotting, respectively. *P<0.05.

Discussion

The human-derived Piwil2 gene was first identified as a stem and testis cell-specific gene (7). As tumor cells and stem cells have the capacity of self-renewal, it is likely that their regulatory mechanisms are similar. Piwil2 is also expressed in several aforementioned tumors. The Piwil2 gene has been highly conserved during evolution and serves as a key factor in maintaining the self-renewal and differentiation of testis and embryonic cells in normal tissue. In addition, Piwil2 has an important role in the development, differentiation and regulation of precancerous stem cells (9). An overexpression of Piwil2 can disturb cell division, and therefore lead to malignant transformation. Piwil proteins have been used as predictive markers for a number of cancers (12,16), particularly for the early detection of disease (6). Furthermore, an overexpression of Piwil2 has been associated with a higher tumor stage and a poorer prognosis (17,18). Despite this, the role of Piwil2 in prostate cancer has been investigated in relatively few studies (6,19).

The present study demonstrated that the Piwil2 gene is highly expressed in surgical tissues and prostate cancer cell lines. Furthermore, it revealed that the level of Piwil2 was positively associated with the Gleason score and TNM stage of the tumor. These results indicate that Piwil2 has a positive role in the development and progression of prostate cancer. Out of the four prostate cancer cell lines that were analyzed, PC-3 cells possess the capacity of high invasion and were derived from bone metastasis, which accounts for up to 90% of all metastatic types of prostate cancer (20). A recombinant lentivirus encoding Piwil2-targeted-shRNA was therefore used to knock down Piwil2 expression in PC-3 cells. As predicted, the results revealed that the inhibition of Piwil2 significantly reduced the invasion and metastasis of PC-3 cells.

A previous study identified that Piwil2 modulated colon cancer metastasis via the regulation of MMP-9 transcriptional activity (14). A further study revealed that MMP-9 in PC-3 cells induced the activity of osteoclasts, and enhanced the invasion of bone metastasis (21). In order to elucidate the potential underlying mechanisms, the present study analyzed the expression of MMPs and consequently identified a downregulation in the expression of MMP-9 in the Piwil2-targeted shRNA PC-3 cells. EMT has gained interest for its involvement in the early steps of invasion and metastasis in malignant tumors of epithelial origin (22). Whether or not Piwil2 activates the process of EMT has yet to be elucidated. Therefore, the present study evaluated the expression of the primary biomarkers of EMT using western blotting and RT-qPCR in the Piwil2-targeted shRNA PC-3 cells. The epithelial marker, E-cadherin, was upregulated, whereas the associated transcription factors involved in EMT, namely vimentin, N-cadherin and Twist, were downregulated.

In summary, the present study revealed that the expression of Piwil2 is positively correlated with the Gleason score and TNM stage of patients with prostate cancer. The Piwil2 gene is involved in the invasion and metastasis of tumor cells by regulating the levels of MMP-9 and modulating EMT. This suggests that Piwil2 participates in tumor aggressiveness and progression. Therefore, Piwil2 may be a novel therapeutic target in the treatment of prostate cancer.

Acknowledgements

This study was supported by grants from the National Natural Science Foundation of China (no. 81272823), and the Henan Science and Technology Research Foundation (no. 122102310047).

References

1 

Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI

2 

Beltran H, Beer TM, Carducci MA, et al: New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol. 60:279–290. 2011. View Article : Google Scholar : PubMed/NCBI

3 

Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI

4 

Chang SS and Kibel AS: The role of systemic cytotoxic therapy for prostate cancer. BJU Int. 103:8–17. 2009. View Article : Google Scholar : PubMed/NCBI

5 

Ni J, Cozzi P, Hao J, et al: Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Int J Biochem Cell Biol. 45:2736–2748. 2013. View Article : Google Scholar : PubMed/NCBI

6 

Lee JH, Schütte D, Wulf G, et al: Stem-cell protein Piwil2 is widely expressed in tumors and inhibits apoptosis through activation of Stat3/Bcl-XL pathway. Hum Mol Genet. 15:201–211. 2006. View Article : Google Scholar : PubMed/NCBI

7 

Cox DN, Chao A, Baker J, et al: A novel class of evolutionarily conserved genes defined by piwi are essential for stem cell self-renewal. Genes Dev. 12:3715–3727. 1998. View Article : Google Scholar : PubMed/NCBI

8 

Sasaki T, Shiohama A, Minoshima S and Shimizu N: Identification of eight members of the Argonaute family in the human genome. Genomics. 82:323–330. 2003. View Article : Google Scholar : PubMed/NCBI

9 

Kuramochi-Miyagawa S, Kimura T, Ijiri TW, et al: Mili, a mammalian member of piwi family gene, is essential for spermatogenesis. Development. 131:839–849. 2004. View Article : Google Scholar : PubMed/NCBI

10 

Liu X, Sun Y, Guo J, et al: Expression of hiwi gene in human gastric cancer was associated with proliferation of cancer cells. Int J Cancer. 118:1922–1929. 2006. View Article : Google Scholar : PubMed/NCBI

11 

He G, Chen L, Ye Y, et al: Piwil2 expressed in various stages of cervical neoplasia is a potential complementary marker for p16. Am J Transl Res. 2:156–169. 2010.PubMed/NCBI

12 

Liu JJ, Shen R, Chen L, et al: Piwil2 is expressed in various stages of breast cancers and has the potential to be used as a novel biomarker. Int J Clin Exp Pathol. 3:328–337. 2010.PubMed/NCBI

13 

Yin DT, Li HQ, Wang YF, et al: Expression of Piwil2 and its relationship with tumor invasion and metastasis in papillary thyroid carcinoma. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 46:237–239. 2011.(In Chinese). PubMed/NCBI

14 

Li D, Sun X, Yan D, et al: Piwil2 modulates the proliferation and metastasis of colon cancer via regulation of matrix metallopeptidase 9 transcriptional activity. Exp Biol Med (Maywood). 237:1231–1240. 2012. View Article : Google Scholar : PubMed/NCBI

15 

General Assembly of the World Medical Association, . World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. J Am Coll Dent. 81:14–18. 2014.PubMed/NCBI

16 

Wang Y, Liu Y, Shen X, et al: The PIWI protein acts as a predictive marker for human gastric cancer. Int J Clin Exp Pathol. 5:315–325. 2012.PubMed/NCBI

17 

Oh SJ, Kim SM, Kim YO and Chang HK: Clinicopathologic implications of PIWIL2 expression in colorectal cancer. Korean J Pathol. 46:318–323. 2012. View Article : Google Scholar : PubMed/NCBI

18 

Greither T, Koser F, Kappler M, et al: Expression of human Piwi-like genes is associated with prognosis for soft tissue sarcoma patients. BMC Cancer. 12:2722012. View Article : Google Scholar : PubMed/NCBI

19 

Shaikhibrahim Z, Lindstrot A, Ochsenfahrt J, Fuchs K and Wernert N: Epigenetics-related genes in prostate cancer: Expression profile in prostate cancer tissues, androgen-sensitive and -insensitive cell lines. Int J Mol Med. 31:21–25. 2013.PubMed/NCBI

20 

Bubendorf L, Schöpfer A, Wagner U, et al: Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 31:578–583. 2000. View Article : Google Scholar : PubMed/NCBI

21 

Dong Z, Bonfil RD, Chinni S, et al: Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am J Pathol. 166:1173–1186. 2005. View Article : Google Scholar : PubMed/NCBI

22 

Boyer B, Vallés AM and Edme N: Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol. 60:1091–1099. 2000. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Yang Y, Zhang X, Song D and Wei J: Piwil2 modulates the invasion and metastasis of prostate cancer by regulating the expression of matrix metalloproteinase-9 and epithelial-mesenchymal transitions. Oncol Lett 10: 1735-1740, 2015.
APA
Yang, Y., Zhang, X., Song, D., & Wei, J. (2015). Piwil2 modulates the invasion and metastasis of prostate cancer by regulating the expression of matrix metalloproteinase-9 and epithelial-mesenchymal transitions. Oncology Letters, 10, 1735-1740. https://doi.org/10.3892/ol.2015.3392
MLA
Yang, Y., Zhang, X., Song, D., Wei, J."Piwil2 modulates the invasion and metastasis of prostate cancer by regulating the expression of matrix metalloproteinase-9 and epithelial-mesenchymal transitions". Oncology Letters 10.3 (2015): 1735-1740.
Chicago
Yang, Y., Zhang, X., Song, D., Wei, J."Piwil2 modulates the invasion and metastasis of prostate cancer by regulating the expression of matrix metalloproteinase-9 and epithelial-mesenchymal transitions". Oncology Letters 10, no. 3 (2015): 1735-1740. https://doi.org/10.3892/ol.2015.3392
Copy and paste a formatted citation
x
Spandidos Publications style
Yang Y, Zhang X, Song D and Wei J: Piwil2 modulates the invasion and metastasis of prostate cancer by regulating the expression of matrix metalloproteinase-9 and epithelial-mesenchymal transitions. Oncol Lett 10: 1735-1740, 2015.
APA
Yang, Y., Zhang, X., Song, D., & Wei, J. (2015). Piwil2 modulates the invasion and metastasis of prostate cancer by regulating the expression of matrix metalloproteinase-9 and epithelial-mesenchymal transitions. Oncology Letters, 10, 1735-1740. https://doi.org/10.3892/ol.2015.3392
MLA
Yang, Y., Zhang, X., Song, D., Wei, J."Piwil2 modulates the invasion and metastasis of prostate cancer by regulating the expression of matrix metalloproteinase-9 and epithelial-mesenchymal transitions". Oncology Letters 10.3 (2015): 1735-1740.
Chicago
Yang, Y., Zhang, X., Song, D., Wei, J."Piwil2 modulates the invasion and metastasis of prostate cancer by regulating the expression of matrix metalloproteinase-9 and epithelial-mesenchymal transitions". Oncology Letters 10, no. 3 (2015): 1735-1740. https://doi.org/10.3892/ol.2015.3392
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team